The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is a huge mover today! The stock decreased 1.96% or $0.49 during the last trading session, hitting $24.55. About 14.49M shares traded hands. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 62.69% since February 29, 2016 and is downtrending. It has underperformed by 73.11% the S&P500.
The move comes after 7 months negative chart setup for the $7.95 billion company. It was reported on Oct, 1 by Barchart.com. We have $23.32 PT which if reached, will make NYSE:VRX worth $397.50M less.
Analysts await Valeant Pharmaceuticals Intl Inc (NYSE:VRX) to report earnings on October, 17. They expect $1.80 earnings per share, down 33.33% or $0.90 from last year’s $2.7 per share. VRX’s profit will be $582.89M for 3.41 P/E if the $1.80 EPS becomes a reality. After $1.40 actual earnings per share reported by Valeant Pharmaceuticals Intl Inc for the previous quarter, Wall Street now forecasts 28.57% EPS growth.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Ratings Coverage
Out of 23 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 9 rate it a “Buy”, 2 “Sell”, while 12 “Hold”. This means 39% are positive. Valeant Pharmaceuticals Intl has been the topic of 73 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating given on Tuesday, March 8 by Mizuho. The firm has “Hold” rating given on Wednesday, March 2 by Canaccord Genuity. The rating was maintained by Scotia Capital on Wednesday, October 14 with “Sector Outperform”. The firm has “Sector Perform” rating by RBC Capital Markets given on Wednesday, March 16. On Tuesday, September 29 the stock rating was initiated by Nomura with “Buy”. The firm has “Neutral” rating given on Thursday, December 17 by Mizuho. The firm has “Underperform” rating by Mizuho given on Monday, March 21. Rodman & Renshaw maintained the shares of VRX in a report on Tuesday, August 9 with “Buy” rating. The firm has “Equal-Weight” rating given on Friday, October 2 by Morgan Stanley. Morgan Stanley maintained the stock with “Equal-Weight” rating in Wednesday, March 16 report.
According to Zacks Investment Research, “Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.”
Insitutional Activity: The institutional sentiment decreased to 0.86 in 2016 Q2. Its down 0.06, from 0.92 in 2016Q1. The ratio turned negative, as 88 funds sold all Valeant Pharmaceuticals Intl Inc shares owned while 97 reduced positions. 52 funds bought stakes while 107 increased positions. They now own 217.59 million shares or 18.89% less from 268.27 million shares in 2016Q1.
Dimensional Fund Advsr L P accumulated 75,483 shares or 0% of the stock. The New York-based Blackrock Inc has invested 0% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Pentwater Management Ltd Partnership holds 1.05% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 3.90M shares. Kazazian Asset Mngmt Limited accumulated 10,165 shares or 0.34% of the stock. Franklin Street Advsrs Inc Nc holds 0.07% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 18,470 shares. Massachusetts Ma holds 0% or 159,936 shares in its portfolio. Hightower Lc holds 64,820 shares or 0.02% of its portfolio. Blackrock Advsr Limited Liability holds 0% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 625 shares. The Ontario – Canada-based Toronto Dominion Comml Bank has invested 0.79% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Wfg Advsr Ltd Partnership has 0.02% invested in the company for 2,877 shares. Acadian Asset Limited Liability Corp reported 186,884 shares or 0.02% of all its holdings. Nationwide Fund Advisors holds 0% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 53,600 shares. Moreover, Meag Munich Ergo Kapitalanlagegesellschaft Mbh has 0.1% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 55,000 shares. Amp Cap Investors has 0.02% invested in the company for 166,512 shares. The Ohio-based Winfield Associates has invested 0% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX).
Insider Transactions: Since June 9, 2016, the stock had 2 insider purchases, and 0 selling transactions for $5.04 million net activity. $98,600 worth of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was bought by KARABELAS ARGERIS N on Thursday, August 11. $4.94M worth of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was bought by PAPA JOSEPH C.
More notable recent Valeant Pharmaceuticals Intl Inc (NYSE:VRX) news were published by: Fool.com which released: “Better Buy: Valeant Pharmaceuticals International, Inc. vs. Endo International plc” on September 30, 2016, also Investorplace.com with their article: “2 Trades to Go Long Valeant Pharmaceuticals Intl Inc (VRX) With Gusto!” published on September 26, 2016, Fool.com published: “3 Reasons Behind Valeant Pharmaceuticals Intl. Inc.’s 30% Ascent in August” on September 08, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (NYSE:VRX) were released by: Investorplace.com and their article: “Valeant Pharmaceuticals Intl Inc (VRX) Just Doesn’t Get it” published on September 19, 2016 as well as Seekingalpha.com‘s news article titled: “Valeant: Is Bankruptcy Possible?” with publication date: September 28, 2016.
VRX Company Profile
Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.